HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load

JAMA

Volumn 286, Issue 20, 2001, Pages 2560-2567

  Phillips, Andrew N ^a   Staszewski, Schlomo ^b   Weber, Rainer ^c   Kirk, Ole ^d   Francioli, Patrick ^e   Miller, Veronica ^b   Vernazza, Pietro ^f   Lundgren, Jens D ^d   Ledergerber, Bruno ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d HVIDOVRE HOSPITAL   (Denmark)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035965669     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.20.2560     Document Type: Article

References (39)

1. Longitudinal HIV-1 load in the Italian Seroconversion Study: Correlates and temporal trends of virus load
2. Longitudinal HIV-1 RNA levels in a cohort of homosexual men
3. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection
4. The course of viral load throughout HIV-1 infection
5. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome
6. The cumulative risk of AIDS as the CD4 lymphocyte count declines
7. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
8. Risk of new AIDS diseases in people on triple therapy
9. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
10. British HIV Association Guidelines for the treatment of HIV infected adults with antiretroviral therapy
11. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel
12. The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics
13. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients
14. Virological response to protease inhibitor therapy in an HIV clinic cohort
15. Multicenter comparison of three commercial methods for quantification of HIV-1 RNA in plasma
16. + T cell response after virologic failure of protease inhibitor-based regimens in patients with HIV infection
17. AIDS across Europe, 1994-98: The EuroSIDA study
18. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
19. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre
20. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
21. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
22. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
23. Predictors of optimal virological response to potent antiretroviral therapy
24. Avanti 2: A randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral naïve patients
25. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
26. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
27. Factors associated with clinical and virological failure in patients receiving triple therapy including a protease inhibitor
28. Predictors of long-term respones to protease inhibitor therapy in a cohort of HIV-infected patients
29. CD4 cell count as a predictor of the duration of highly active antiretroviral therapy induced suppression of HIV virus load
30. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population
31. Predictors of virological success and ensuing failure among HIV positive patients starting HAART in Europe: Results from the EuroSIDA study
32. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia: The Swiss HIV Cohort Study
33. Predicting the duration of antiretroviral treatment needed to suppress plasma HIV-1 RNA
34. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study
35. Influence of age on CD4 cell recovery in HIV-infected patients receiving HAART: Evidence from the EuroSIDA study
36. Why is highly active antiretroviral therapy not prescribed or discontinued?
37. + lymphocytes as prognostic markers of HIV-1 infection
38. + cells among persons with hemophilia